List of hepato-biliary diseases

À propos
Confidentialité
Mentions légales

Graph Chatbot

Publications associées (29)

The therapeutic role of NAD+ modulation in fatty liver disease

Karim Laurent Gariani

NAFLD encompasses a disease spectrum ranging from hepatic steatosis to nonalcoholic steatohepatitis (NASH), fibrosis, and finally cirrhosis, which predisposes to the development of hepatocellular carcinoma. With no approved pharmacological treatment, NAFLD ...

EPFL2017

Impaired SUMOylation of nuclear receptor LRH-1 promotes nonalcoholic fatty liver disease

Kristina Schoonjans, Pan Xu, Vera Monica Lemos Da Silva, Hadrien Charles Edouard Demagny, Dongryeol Ryu, Xu Wang, Matthias Alexander Sokrates Stein, Maaike Hélène Oosterveer

Hepatic steatosis is caused by metabolic imbalances that could be explained in part by an increase in de novo lipogenesis that results from increased sterol element binding protein 1 (SREBP-1) activity. The nuclear receptor liver receptor homolog 1 (LRH-1) ...

Amer Soc Clinical Investigation Inc2017

Ammonia toxicity: from head to toe?

Peter Ott, Veronika Rackayová

Ammonia is diffused and transported across all plasma membranes. This entails that hyperammonemia leads to an increase in ammonia in all organs and tissues. It is known that the toxic ramifications of ammonia primarily touch the brain and cause neurologica ...

Springer Verlag2017

Inhibiting poly ADP-ribosylation increases fatty acid oxidation and protects against fatty liver disease

Johan Auwerx, Kristina Schoonjans, Alessia Perino, Dongryeol Ryu, Vera Monica Lemos Da Silva, Elena Katsyuba, Jun Yong Kim, Hongbo Zhang, Pooja Jha, Keir Joe Menzies, Matthias Alexander Sokrates Stein, Karim Laurent Gariani

Background & Aims: To date, no pharmacological therapy has been approved for non-alcoholic fatty liver disease (NAFLD). The aim of the present study was to evaluate the therapeutic potential of poly ADP-ribose polymerase (PARP) inhibitors in mouse models o ...

Elsevier Science Bv2017

PARP inhibition protects against alcoholic and non-alcoholic steatohepatitis

Johan Auwerx, Dongryeol Ryu, Wei Wang, Karim Laurent Gariani, Zhou Zhou

Background & Aims: Mitochondria) dysfunction, oxidative stress, inflammation, and metabolic reprograming are crucial contributors to hepatic injury and subsequent liver fibrosis. Poly(ADP-ribose) polymerases (PARP) and their interactions with sirtuins play ...

Elsevier Science Bv2017

(1)H and (31)P magnetic resonance spectroscopy in a rat model of chronic hepatic encephalopathy: in vivo longitudinal measurements of brain energy metabolism

Cristina Ramona Cudalbu, Bernard Lanz, Veronika Rackayová, Corina Mihaela Berset

Chronic liver disease (CLD) leads to a spectrum of neuropsychiatric disorders named hepatic encephalopathy (HE). Even though brain energy metabolism is believed to be altered in chronic HE, few studies have explored energy metabolism in CLD-induced HE, and ...

Springer Verlag2016

Brain edema: a valid endpoint for measuring hepatic encephalopathy?

Cristina Ramona Cudalbu

Hepatic encephalopathy (HE) is a major complication of liver failure/disease which frequently develops during the progression of end-stage liver disease. This metabolic neuropsychiatric syndrome involves a spectrum of symptoms, including cognition impairme ...

Springer Verlag2016

New technologies – new insights into the pathogenesis of hepatic encephalopathy

Bernard Lanz

Hepatic encephalopathy (HE) is a neuropsychiatric syndrome which frequently accompanies acute or chronic liver disease. It is characterized by a variety of symptoms of different severity such as cognitive deficits and impaired motor functions. Currently, H ...

Springer Verlag2016

Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance

Kristina Schoonjans, Alessia Perino

The systemic expression of the bile acid (BA) sensor farnesoid X receptor (FXR) has led to promising new therapies targeting cholesterol metabolism, triglyceride production, hepatic steatosis and biliary cholestasis. In contrast to systemic therapy, bile a ...

Nature Publishing Group2015

Page 2 sur 2